ClinicalTrials.gg
RecruitingNCT07947992Updated Nov 19, 2026

Efficacy of Topical Metformin 30% Versus Minoxidil 5% in the Treatment of Alopecia Areata : Comparative Study

An interventional study of Metformin 30% Topical Lotion and Minoxidil 5 % Topical Spray in Alopecia Areata(AA), sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Sohag University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 32 studies in Alopecia Areata with a site in Egypt — 8 open to participants now, 9 under way, none of them phase 3. Alopecia Areata · Egypt.

Planned enrollment
10th of 30
60 · median 50
Started
2026
the only one that year
No phase
15 of 32
5 open now
Registered
32nd of 32
by date
Lead sponsor
6 of 32
Sohag University

Among the 32 studies in Alopecia Areata with a site in Egypt, this one is the 10th largest by planned enrollment of the 30 interventional ones that give a count, is the only one that started in 2026, is one of 15 with no phase, and was the 32nd registered.

Alopecia Areata

221 studies on the registry are indexed under Alopecia Areata; 62 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

8 of the 32 studies in Alopecia Areata with a site in Egypt are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 42 Alopecia Areata studies recruiting now, 17 (40%) set no upper age limit and 21 (50%) stop at 75 or younger; 20 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Alopecia Areata with a site in Egypt, or all of them as a file.
02

Study summary

This study aims to evaluate and compare the effectiveness and safety of topical metformin 30% and topical minoxidil 5% in patients with alopecia areata.

Alopecia areata is an autoimmune condition that causes non-scarring hair loss, usually presenting as round or oval patches on the scalp. Different topical treatments are used to stimulate hair regrowth, but their effectiveness varies.

In this comparative interventional study, eligible patients with alopecia areata will receive either topical metformin 30% or topical minoxidil 5%. Treatment response will be assessed clinically during follow-up using standardized assessment methods, including the Severity of Alopecia Tool (SALT) score, along with clinical and dermoscopic evaluation.

The study aims to determine whether topical metformin 30% is an effective treatment option compared with topical minoxidil 5% in patients with alopecia

03

Conditions studied

  • Alopecia Areata(AA)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged above 18 years to 40 years
  2. Both sexes.
  3. Patients with a clinical and dermoscopic diagnosis of localized alopecia areata.

Exclusion criteria

Exclusion Criteria:

  1. Patients who received systemic or topical treatment for alopecia areata during the previous three months before the start of the study.
  2. Pregnant or lactating women.
  3. Patients with bleeding or coagulation disorders.
  4. Patients with diseases.
  5. Patients with liver or renal diseases.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Topical Metformin 30%

    Participants assigned to this arm will receive topical metformin 30% for the treatment of alopecia areata.

    Drug: Metformin 30% Topical Lotion

  • Active comparator
    Topical Minoxidil 5%

    Participants assigned to this arm will receive topical minoxidil 5% for the treatment of alopecia areata.

    Drug: Minoxidil 5 % Topical Spray

Interventions

  • DrugMetformin 30% Topical Lotion

    Topical metformin 30% preparation used for the treatment of alopecia areata.

  • DrugMinoxidil 5 % Topical Spray

    Topical minoxidil 5% preparation used for the treatment of alopecia areata.

06

What researchers measure

Primary outcomes

  1. Change in SALT Score from Baseline to Week 12

    Assessment of the change in Severity of Alopecia Tool (SALT) score from baseline to week 12 to evaluate the therapeutic response to topical metformin 30% compared with topical minoxidil 5%. A decrease in SALT score indicates improvement in scalp hair loss.

    Time frame: Baseline to Week 12 (12 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Nov 2027, 12 months after the start.

Of 21 interventional studies with no phase under Alopecia Areata, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartActual
Oct 29, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947992
Lead sponsor
Sohag University
Responsible party
Arwa Ahmed Mohamed (resident of dermatology, venerelogy and andrology, Sohag University) — Principal investigator
First posted
Nov 19, 2026
Start date
Oct 29, 2026
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Nov 19, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion